IRB #

IRB00005688

Title

A Phase II study of MAOA inhibitor plus docetaxel in patients currently receiving and progressing on docetaxel therapy

Principal Investigator

Tomasz Beer

Study Purpose

The purpose of this study is to learn if the study drug (phenelzine) can restore chemotherapy sensitivity in patients who are beginning to progress on standard docetaxel chemotherapy.

Medical Condition(s)

Prostate

Eligibility Criteria

* Subjects will have confirmed andenocarcinoma of the prostate that has spread outside the prostate and is no longer responding to hormone therapy.
*Subject must have evidence of progression during (while on therapy or within 45 days of the last dose administered) docetaxel therapy
*Subject must be willing to undergo a baseline tumor biopsy
*Subject must enroll in the study within 3 months of last docetaxel dose

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Wayne D. Kuni and Joan E. Kuni Foundation

Recruitment End

Compensation Provided

No